Biotech Startups

Fattastic Technologies, founded in 2022, develops plant-based fat ingredients for use in food and other applications. It creates alternative fat formulations from plant-based oils for the food and ingredient industry.

3 investors

Fecundis is a biotechnology company developing sperm-centered technologies for assisted reproduction, including HyperSperm, a sequential-step kit that recreates physiological sperm capacitation in vitro for IVF and ICSI. Its products are aimed at IVF laboratories and fertility clinics to improve sperm function, embryo quality, and ART outcomes.

3 investors

Feldan is a clinical-stage biotech company developing intracellular delivery technologies for therapeutic treatment of diseases. The company specializes in its Feldan Shuttle peptide-based technology to deliver antisense oligonucleotides and other therapeutics to cellular targets, with current programs targeting basal cell carcinoma and respiratory diseases.

3 investors

Felix Biotechnology develops a digital platform for designing viruses intended to combat antimicrobial resistance.

3 investors

Fieldstone Bio builds engineered biosensors combined with hyperspectral imaging to detect and map critical minerals such as gold, copper, and arsenic in soil samples, cores, and tailings. The platform serves mining and mineral exploration teams, providing high-resolution measurement data to guide sampling, drilling, and processing decisions.

3 investors

First Light Diagnostics develops the MultiPath benchtop analyzer, an instrument for rapid diagnostic testing. The company operates in the in-vitro diagnostics space.

3 investors

Flare Therapeutics develops small molecule medicines targeting transcription factors using a chemistry and proteomics platform that enables ligand discovery directly from cells. The company has lead programs in prostate cancer and advanced urothelial cancer, and maintains a partnership with Roche.

3 investors

Flex Pharma provides accessible generic vasodilator medications, including PDE5 inhibitors, to U.S. patients at lower costs than brand-name alternatives. The company focuses on vessel health and blood flow optimization for applications ranging from athletic performance to sexual wellness.

3 investors

FLOWBIO makes a wearable sensor that captures continuous sweat data during exercise, recording measurements every 8 seconds across an entire training session or race. It is aimed at athletes seeking real-time hydration and sweat insights rather than single-point tests.

3 investors

FluoSphera develops in vitro human biology solutions for drug discovery, applying translational research to improve preclinical decision-making. The company serves pharmaceutical and biotech organizations seeking more predictive biological models.

3 investors

Foldax develops heart valve replacement technology leveraging polymer expertise and biologic design. The company targets patients who require valve replacement, particularly young women with rheumatic disease in developing countries and aging patients in developed markets facing multiple surgeries.

3 investors

A venture capital firm investing in biotech companies across all stages of pharmaceutical development, and in sustainable solutions across food, agriculture, materials, and environmental technologies through its BioEconomy strategy.

3 investors

Forge Biologics is a US-based gene therapy CDMO (contract development and manufacturing organization) offering AAV manufacturing services, technologies, and infrastructure. It supports gene therapy developers across early development, clinical trials, and commercial production, and is a subsidiary of the Ajinomoto Group.

3 investors

Fortis Therapeutics develops therapeutic treatments based on technology licensed from UCSF, with a focus on oncology and other disease areas. The company is backed by multiple life sciences investment firms and operates from San Diego.

3 investors

FoRx Therapeutics is a biotechnology company focused on oncology drug discovery and clinical development, targeting the DNA Damage Response (DDR) network with small molecule inhibitors. Its work centers on cancer therapeutics developed by a team with pharma and biotech backgrounds.

3 investors

Freeline develops gene therapies aimed at stopping the progression of chronic diseases with single-dose genetic medicines. Its pipeline spans rare conditions such as Gaucher disease and moves toward more widespread conditions including forms of Parkinson's, dementia, and certain cardiovascular diseases.

3 investors

Funga restores forest soil microbiomes by reintroducing native, growth-promoting fungal communities to degraded land, aiming to speed forest growth and increase carbon captured in wood biomass. It uses biodiversity restoration as a carbon-removal climate solution.

3 investors

Future Fertility develops an artificial intelligence tool to assess egg quality for fertility treatment using machine learning analysis of oocyte health. The company serves reproductive endocrinologists, embryologists, and patients undergoing IVF procedures.

3 investors

G2GBIO (Good to the Globe Biotech) is a pharmaceutical company developing improved new drug injectable formulations, with platform technology applicable to treatments for various diseases and mass-production techniques. It focuses on supplying medicines under a "Humanity First" vision.

3 investors

GAIA BioMedicine (株式会社ガイアバイオメディシン) develops GAIA-NK, a cell therapy using engineered cells with high cytotoxic activity against solid tumors, based on research from Kyushu University. The company researches, develops, and manufactures regenerative medicine products aimed at curative cancer treatment.

3 investors

3 investors

Galera Therapeutics is a biotechnology company developing antibody-based and other therapeutics. This page profiles Dr. Nancy Chang, a member of the company's Board of Directors.

3 investors

Gandeeva Therapeutics uses AI, machine learning, and atomic-resolution cryo-EM imaging to map druggable protein interactions and design molecular glues that bind at specific protein interfaces. The company applies this drug-discovery approach to develop precision medicines against targets such as protein-protein complexes, nucleic acid-protein complexes, and membrane proteins.

3 investors

Gatehouse Bio develops AI-powered therapeutics for pulmonary, cardiac, neurological, and autoimmune diseases by decoding small RNAs using their Code-Breaker platform to design precision medicine treatments.

3 investors